Neumora Therapeutics is a clinical-stage biopharmaceutical company. Co. has scaled its therapeutic pipeline, which consists of seven clinical and preclinical neuroscience programs that target mechanisms of action for a range of neuropsychiatric disorders and neurodegenerative diseases. Co.'s primary product candidate, navacaprant (NMRA-140), is a once-daily oral kappa opioid receptor antagonist that is being developed for the treatment of major depressive disorder (MDD). Co. is initiating a Phase 3 program for navacaprant monotherapy in patients with moderate to severe MDD. We show 3 historical shares outstanding datapoints in our NMRA shares outstanding history coverage, used to compute NMRA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NMRA market cap history over the course of time is important for investors
interested in comparing NMRA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NMRA versus a peer is one thing; comparing
NMRA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NMRA can fluctuate over the course of history.
With this page we aim to empower investors researching NMRA by allowing them to research the NMRA market cap history. |
Free NMRA Email Alerts:
Video: The Importance of Market Cap
